WHO ICTRP trial
An open-label, multicenter, phase II study of trametinib and dabrafenib in…
KCT0003021 · Clinical Research Information Service (CRIS) · Recruiting
Key facts
| Trial ID | KCT0003021 |
|---|---|
| Public title | An open-label, multicenter, phase II study of trametinib and dabrafenib in patients with non-small cell lung cancer harboring V600 BRAF mutation |
| Scientific title | An open-label, multicenter, phase II study of trametinib and dabrafenib in patients with non-small cell lung cancer harboring V600 BRAF mutation |
| Primary sponsor | Asan Medical Center |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Recruiting |
| Study type | Interventional Study |
| Phase | Phase2 |
| Countries | Korea, Republic of |
| Conditions | Neoplasms |
| Interventions | Drug : Clinical trials are oral medications. Daily doses are 150 mg twice daily for dabrafenib and 2 mg daily for trametinib. Drugs are taken 1 hour before meals or 2 hours after meals. A daily dose of trametinib can be taken at the same… |
| Registration date | Jul 24, 2018 |
| Target size | 27 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: